NVCT · Nuvectis Pharma Inc
United States · RS rating 83 · As of 2026-11-03
| Price | 19.34 USD |
|---|---|
| 1-day change | +0.8% |
| RS rating (overall / 1M / 3M / 12M) | 83 / 36 / 67 / 97 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 34 / 38 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -15.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +32.2% |
| Market cap (USD) | $232.9M |